eunice wang md

Eunice Wang, MD, shares exciting data for acute myeloid leukemia (AML) presented at ASH 2017

Eunice Wang, MD, on next-generation sequencing and treatment selection in AML

Eunice Wang, MD, on how minimal residual disease is being integrated into treatment decisions in AML

Eunice Wang, MD, on the importance of drug potency in the treatment of FLT3-ITD positive AML

Eunice Wang, MD, on the role of nivolumab maintenance in high-risk AML patients

Searching for Effective Treatment in Newly Diagnosed FLT3 Positive AML | Eunice Wang | ASH 2021 #AML

Eunice Wang, MD, talks about the challenges in treating elderly patients with AML

Eunice Wang, MD, on Treating AML During the COVID-19 Pandemic

Dr Ravi Vij MD, is Discussing with Dr. Eunice Wang MD, on Acute Myeloid Leukemia:Targeted Therapies

Eunice Wang, MD, considers approaches for clinicians when managing frail AML patients

Eunice Wang, MD, on incorporating Vyxeos (liposomal daunorubicin and cytarabine) in AML treatment

Dr. Eunice Wang | Spend Just One Day With Us

Eunice S. Wang, MD, discusses CPX-351 (Vyxeos) mechanism of action and why it is a promising agent

Eunice Wang, MD, tells us about the most exciting data coming out of the 2018 ASCO Annual Meeting

Eunice Wang, MD, on exciting news stemming from this year’s ASH meeting in the treatment for ALL

What Should I Do if I Have to Find a New Cancer Treatment Provider?

Professor Eunice Wang, M.D. - Phase III CASCADE study

Molecular Targets for Personalized Treatment of AML (Acute Myeloid Leukemia)

Types of Leukemia Treatment at Roswell Park

Eunice Wang | ASCO 2018 | What are the new advances in AML treatment?

Decision-Making in AML: What's Next After Relapse I Dr. Eunice Wang - MRD Status #AML

Why Roswell Park for Leukemia Care?

AML Research and Emerging Treatment Options: An Expert’s Perspective

Dr. Wang on Results With Crenolanib Plus Chemotherapy in AML